



PAEDIATRIC ANTI-TB DRUGS AN INCLUSIVE APPROACH

SUPPLYING APPROPRIATE ANTI-TB DRUGS
FOR CHILDREN



TECHNICAL ASSISTANCE A HOLISTIC APPROACH

WORKING CLOSELY WITH PROGRAMMES
AND PARTNERS TO STRENGTHEN DRUG
MANAGEMENT SYSTEMS



THE GLOBAL DRUG FACILITY COMPARATIVE ADVANTAGES



1ST AND 2ND LINE ANTI-TB DRUGS

PROVIDING AN UNINTERRUPTED
SUPPLY OF GDF AND GREEN LIGHT COMMITTEE
APPROVED ANTI-TUBERCULOSIS (TB) DRUGS OF
ASSURED QUALITY

Global Drug Facility
Stop TB Partnership
c/o World Health Organization
20 Avenue Appia
1211 Geneva 27
Switzerland

www.stoptb.org/gdf
gdf@who.int



GDF is ISO
9001:2000 certified

Stop TB Partnership



© WHO WHO/HTM/STB/2009.56

The Global Drug Facility (GDF), an arm of the **Stop TB Partnership**, ensures access to high-quality anti-TB drugs, at the lowest possible price, for countries in need. Launched in 2001, GDF has developed an innovative approach to furnishing the drugs and supplies needed to fully implement the World Health Organization's Stop TB Strategy. GDF has provided anti-TB drugs to 95 countries, including 18 of the 22 countries bearing the highest burden of TB.

GDF offers a unique package of services. Through its Grant Service, GDF provides life-saving anti-TB drugs free of charge to countries that cannot afford to pay for them. Countries that have sufficient finances but lack adequate procurement capacity and a robust quality assurance system can use GDF's Direct Procurement Service, which assures access to the same high-quality anti-TB drugs, fast lead times and low prices. In both cases, GDF provides technical assistance for in-country drug management and monitoring. GDF unites these three essential services, with aligned decision-making, under one umbrella.

WHAT GDF OFFERS

A Grant Service through which countries can apply to receive free grants of first-line anti-TB drugs (adult and paediatrics), rather than first having to apply for funding to purchase them.

A Direct Procurement Service through which governments, donors and NGOs that have the necessary financial means but lack adequate procurement capacity can purchase high-quality anti-TB drugs and diagnostics.

Technical assistance aimed at helping countries achieve good drug management by addressing systemic problems and establishing long-term health system strategies.

Transitional grants of first-line anti-TB drugs to countries waiting for disbursement of funds from donor agencies such as the Global Fund to fight AIDS, Tuberculosis and Malaria.

Emergency grants of anti-TB drugs to countries facing stock-outs because of humanitarian crises, for example.

The mandated procurement service of the Green Light Committee (GLC) Initiative for second-line anti-TB drugs to treat multidrug-resistant TB via grants from the Global Fund.

Technical assistance to manufacturers and suppliers trying to improve the quality of their anti-TB drugs.

Strategic stockpiles of key first and second-line drugs to meet urgent, short-term demand.

A Strategic Revolving Fund to provide provisional, reimbursable lines of credit to eligible countries for the purchase of second-line drugs to treat MDR-TB.



COMPETITIVE PRICING
SIGNIFICANT SAVINGS
POOLING PROCUREMENT ENABLES
GDF TO OFFER THE MOST COMPETITIVE
PRICES, TO ALL

GDF'S COMPARATIVE ADVANTAGES

GDF is more than a funding agency – its Grant Service combines the financing AND procurement of quality-assured anti-TB drugs.

GDF provides anti-TB drugs to countries that lack the resources required for purchasing them and are ineligible for funding from certain donor agencies, or financing mechanisms.

GDF competitively and transparently contracts procurement agents, manufacturers and service providers.

GDF helps countries access needed anti-TB drugs quickly because there is a single, simple application procedure rather than separate procedures for funding and drug procurement.

GDF combines supply of anti-TB drugs with the technical assistance necessary to manage those drugs effectively within countries.

GDF can offer fast-track service – for example, rapid support to countries that are waiting for disbursement of funds from donors to be able to order and receive drugs, or countries that are suffering from shortages due to civil strife or other humanitarian crises.

GDF provides, exclusively, drugs that have either been prequalified by the WHO's Prequalification Programme, approved by a stringent national drug regulatory authority or have passed a provisional evaluation by an independent expert committee commissioned by WHO at GDF's request.

GDF's manufacturers have innovative and dedicated GDF-specific processes and technology for manufacturing and packaging of anti-TB drugs. This includes Stop TB Patient Kits and special blister packs.

GDF can guarantee the lowest possible prices and timely procurement because demand is pooled and limited to a standardized list of drugs.

GDF offers "one-stop access" for the first- and second-line anti-TB drugs, adult and paediatric formulations, and TB diagnostics needed by a TB control programme.

DIAGNOSTIC KITS

CASE-FINDING REDEFINED

OFFERING PRACTICAL DIAGNOSTIC TOOLS FOR
LABORATORIES TO IMPROVE CASE-FINDING

